Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 6, 2004, Pages 497-510

  Silva, Matthew A ^a   Gandhi, P J ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

"GP 111b 111a inhibitor"; "non st segment elevation myocardial infarction"; Eptifibatide; Tirofiban; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOXANE A2; TIROFIBAN;

BLEEDING; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; INFLAMMATION; METHODOLOGY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; UPREGULATION;

ANGINA, UNSTABLE; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TYROSINE;

EID: 10844265216     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00594.x     Document Type: Review

References (80)

1. Eyre H, Kahn R, Roberston RM (2004) Preventing cancer, cardiovascular disease, and diabetes. A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation, 109, 3244-3255.
2. Barzilay JI, Kronmal RA, Bittner V et al. (1994) Coronary artery disease and coronary artery bypass grafting in diabetic patients aged >65 years (report from the coronary artery surgery study [CASS] registry). American Journal of Cardiology, 74, 334-339.
3. Waller BF, Palumbo PJ, Lie JT et al. (1980) Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without evidence of coronary heart disease and comparison to 183 control subjects. American Journal of Medicine, 69, 498-506.
4. Granger CB, Califf RM, Young S et al. (1993) Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial infarction (TAMI) Study Group. Journal of the American College of Cardiology, 21, 920-925.
5. Mueller HS, Cohen LS, Braunwald E et al. (1992) Predictors of early mortality and morbidity after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation, 85, 1254-1264.
6. Stein B, Weintraub WS, Gebhart SP et al. (1995) Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation, 91, 979-989.
7. Vigorito C, Betocchi S, Bonzani G et al. (1980) Severity of coronary artery disease in diabetic patients mellitus. Angiographic study of 34 diabetic and 120 non-diabetic patients. American Heart Journal, 100, 782-787.
8. Chesebro JH, Fuster V (1991) Dynamic thrombosis and thrombolysis. Role of antithrombins [Editorial]. Circulation, 83, 1815-1817.
9. Simes RJ, Topol EJ, Holmes DR et al. (1995) Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation, 91, 1329-1338.
10. Anderson HV, Willerson JT (1993) Thrombolysis in acute myocardial infarction. New England Journal of Medicine, 329, 703-709.
11. Zuanetti G, Latini R, Maggioni AP et al. (1993) Influence of diabetes on mortality in acute myocardial infarction, data from the GISSI-2 study. Journal of the American College of Cardiology, 22, 1788-1794.
12. Gray RP, Yudkin JS, Patterson DL (1993) Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction, a role for plasminogen activator inhibitor? British Heart Journal, 70(6), 530-536.
13. Ouriel K, Shortell CK, Azodo MV et al. (1994) Acute peripheral arterial occlusion, predictors of success in catheter-directed thrombolytic therapy. Radiology, 193, 561-566.
14. Lincoff MA, Topol EJ (1993) Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction. Circulation, 88, 1361-1374.
15. Coller BS (1990) Platelet and thrombolytic therapy. New England Journal of Medicine, 322, 33-42.
16. Fuster V (1994) Mechanisms leading to myocardial infarction, insights from studies of vascular biology. Circulation, 90, 2126-2146.
17. Lee RT, Libby P (1997) The unstable atheroma. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 1859-1867.
18. Davies MJ (1990) A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation, 82(Suppl. 3), 1138-1146.
19. Davies MJ, Richardson PD, Woolf N et al. (1993) Risk of thrombosis in human atherosclerotic plaques, role of extracellular lipid, macrophage, and smooth muscle cell content. British Heart Journal, 69, 377-381.
20. Loree HM, Tobias BJ, Gibson LJ et al. (1994) Mechanical properties of model atherosclerotic lesion lipid pools. Arteriosclerosis, Thrombosis, and Vascular Biology, 14, 230-234.
21. Khoo JC, Miller E, McLoughlin P et al. (1988) Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis, 8, 348-358.
22. Khoo JC, Miller E, Pio F et al. (1992) Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arteriosclerosis, Thrombosis, and Vascular Biology, 12, 1258-1266.
23. Morel DW, Hessler JR, Chisholm GM (1983) Low-density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. Journal of Lipid Research, 24, 1070-1076.
24. Griendling KK, Alexander RW (1997) Oxidative stress and cardiovascular disease. Circulation, 96, 3262-3265.
25. Eckel RH, Wassef M, Chait A et al. (2002) AHA Conference Proceedings, Prevention Conference VI; Diabetes and Cardiovascular Disease Writing Group II, Pathogenesis of atherosclerosis in diabetes. Circulation, 105, e138-e143.
26. Braunwald E, Antman EM, Beasley JW et al. (2002) ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction, a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Unstable Angina. Available at: http://www. acc.org/clinical/guidelines/unstable/unstable.pdf (accessed September 28, 2004).
27. Peterson ED, Pollack CV, Roe MT, Parsons LS, Littrell KA, Canto JG, Barron HV (2003) Early use of glycoprotein IIb/IIIa Inhibitors in non-ST-elevation acute myocardial infarction, observations from the National Registry of Myocardial Infarction 4. Journal of the American College of Cardiology, 42, 45-53.
28. Cohen M, Gensini GF, Maritz F et al. (2003) Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Circulation 108(Suppl. 1), 14-21.
29. KAA Fox, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A (2002) Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). European Heart Journal, 23, 1177-1189.
30. Aronson D, Rayfield EJ, Chesebro JH (1997) Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Annals of Internal Medicine, 126, 296-306.
31. Tschöepe D, Driesch E, Schwippert B et al. (1995) Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. Diabetes, 44, 890-894.
32. Tschöepe D, Roesen P, Esser J et al. (1991) Large platelets circulate in an activated state in diabetes mellitus. Seminars in Thrombosis and Hemostasis, 17, 433-438.
33. Davì, Catalano I, Averna M et al. (1990) Thromboxane biosynthesis and platelets function in type II diabetes mellitus. New England Journal of Medicine, 322, 1769-1774.
34. Shukla SD, Paul A, Klachko DM (1992) Hypersensitivity of diabetic human platelets to platelet activating factor. Thrombosis Research, 66, 239-246.
35. Davì G, Gresele P, Violi F et al. (1997) Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo: evidence derived from the study of peripheral vascular disease. Circulation, 96, 69-75.
36. Lefkovits J, Plow EF, Topol EJ (1995) Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. New England Journal of Medicine, 332, 1553-1559.
37. Stehouwer CD, Nauta JJ, Zeldenrust GC et al. (1992) Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet, 340, 319-323.
38. Conlan MG, Folsom AR, Finch A et al. (1993) Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Thrombosis and Haemostasis, 70, 380-385.
39. Seiler C, Hess OM, Buechi M et al. (1993) Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation, 88, 2139-2148.
40. Vita JA, Treasure CB, Nabel EG et al. (1990) Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation, 81, 491-497.
41. Harker LA (1987) Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. American Journal of Cardiology, 60, 20B-28B.
42. Cambria-Kiely JA, Gandhi PJ (2002) Possible mechanisms of aspirin resistance. Journal of Thrombosis and Thrombolysis, 13, 49-56.
43. Eckel RH, Wassef M, Chait A et al. (2002) Prevention Conference VI Diabetes and Cardiovascular Disease Writing Group II: Pathogenesis of atherosclerosis in diabetes. Circulation, 105, e138-e143.
44. The GUSTO-IV ACS Investigators. (2001) Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO-TV ACS randomised trial. Lancet, 357, 1915-1924.
45. Coller BS, Peerschke EI, Scudder LE, Sullivan CA (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. Journal of Clinical Investigation, 72, 325-338.
46. Mascelli MA Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE (1998) Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation, 97, 1680-1688.
47. Tcheng JE, Ellis SG, George BS et al. (1994) Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation, 90, 1757-1764.
48. Tcheng JE, Kereiakes DJ, Braden GA et al. (1999) Readministration of abciximab: interim report of the ReoPro readministration registry. American Heart Journal 138 (1 Pt 2), S33-S38.
49. Scarborough RM, Rose JW, Hsu MA et al. (1991) Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. Journal of Biological Chemistry, 266, 9359-9362.
50. Phillips DR, Scarborough RM (1997) Clinical pharmacology of eptifibatide. The American Journal of Cardiology, 80(Suppl. 4A), 11B-20B.
51. Scarborough RM (1999) Development of eptifibatide. American Heart Journal, 138, 1093-1104.
52. Proimos G (2001) Platelet aggregation inhibition with glycoprotein IIb-IIIa inhibitors. Journal of Thrombosis and Thrombolysis, 11, 99-110.
53. Kabbani S, Aggarwal A, Terrien EF et al. (2002) Sub-optimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Journal of the American College of Cardiology, 89, 647-650.
54. Topol EJ, Molniterno DJ, Herrmann HC et al. (2001) Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine, 344, 1888-1894.
55. Deckelbaum LI, Sax FL, Grossman W (1997) Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIa receptor. In: Sasahara AA, Loscalzo J, eds. New therapeutic agents in thrombosis and thrombolysis. New York, NY: Marcel Dekker, 355-365.
56. The PRISM Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New England Journal of Medicine, 338, 1498-1505.
57. The PRISM-PLUS Study Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine, 338, 1488-1497.
58. Kereiakes DJ, Broderick TM, Roth EM et al. (1999) Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. American Journal of Cardiology, 84, 391-395.
59. The PURSUIT Steering Committee (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using Integrilin therapy. New England Journal of Medicine, 339, 436-443.
60. Phillips DR, Teng W, Arfsten A et al. (1997) Effect of Ca2+ on GP IIb-IIIa interactions with Integrelin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation, 96, 1488-1494.
61. Steinhubl S, Talley D, Keriakes D et al. (2000) A prospective multicentre study to determine the optimal level of platelet inhibition with GP IIb/IIIa receptors in patients undergoing coronary intervention. The GOLD study (abstract). Journal of the American College of Cardiology, 35, 44A.
62. Coller BS (1999) Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions. Thrombosis and Haemostasis, 82, 326-336.
63. Kereiakes DJ, Kleiman NS, Ambrose J et al. (1996) Randomized, double-blind, placebo-controlled, dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. Journal of the American College of Cardiology, 27, 536-542.
64. Jennings LK, Jacoski MV, McCabe-White M (2002) The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. Journal Intervention Cardiology, 15, 45-60.
65. Bahou WF, Coller BS, Potter CL et al. (1993) The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation. Journal of Clinical Investigation, 91, 1405-1413.
66. Hawiger J (1987) Formation and regulation of platelet and fibrin hemostatic plug. Human Pathology, 18, 111-122.
67. Tcheng JE, Thel MC, Jennings L et al. (1997) Platelet glycoprotein IIb/IIIa receptor blockade with high-dose INTEGRELIN in coronary intervention: results of the PRIDE study (abstract). European Heart Journal, 18(Suppl.), 624.
68. Tardiff BE, Jennings LK, Harrington RA et al. (2001) Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from the PURSUIT trial. Circulation, 104, 399-405.
69. 3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation, 106, 2111-2117.
70. Nannizzi-Alaimo L, Alves VL, Phillips DR (2003) Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 Ligand during platelet stimulation. Circulation, 107, 1123-1128.
71. Schonbeck U, Varo N, Libby P et al. (2001) Soluble CD40L and cardiovascular risk in women. Circulation, 104, 2266-2268.
72. Schonbeck U, Sukhova GK, Shimizu K et al. (2000) Inhibition of CD40 signalling limits evolution of established atherosclerosis in mice. Proceedings of the National Academy of Sciences of the USA, 97, 7458-7463.
73. Garlichs CD, Eskafi S, Raaz D et al. (2001) Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart, 86, 649-655.
74. Aukrust P, Waehre T, Damas JK et al. (2001) Inflammatory role of platelets in acute coronary syndromes. Heart, 86, 605-606.
75. Nannizzi-Alaimo L, Rubenstein MH, Alves VL et al. (2002) Cardiopulmonary bypass induces the release of soluble CD40 ligand. Circulation, 105, 2849-2854.
76. Urbich C, Dernbach E, Aicher A et al. (2002) CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation, 106, 981-986.
77. 3 integrin-dependent mechanism. Nature Medicine, 8, 247-252.
78. Roe MT, Christenson RH, Ohman EM et al. (2003) A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. American Heart Journal, 146, 993-998.
79. Gurbel PA, Galbut B, Bliden KP et al. (2002) Effect of eptifibatide for acute coronary syndromes: rapid versus late administration-therapeutic yield on platelets (the EARLY platelet substudy). Journal of Thrombosis and Thrombolysis, 14, 213-219.
80. Keating FK, Whitaker DA, Sobel BE, Schneider DJ (2004) Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes. Thrombosis Research, 113, 27-34.